Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

AbCellera Biologics (ABCL) Stock Forecast & Price Target

AbCellera Biologics logo
$11.82 -0.11 (-0.88%)
As of 03:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbCellera Biologics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
2
Buy
7

Based on 10 Wall Street analysts who have issued ratings for AbCellera Biologics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 2 have given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for ABCL.

Consensus Price Target

$13.89
17.45% Upside
According to the 10 analysts' twelve-month price targets for AbCellera Biologics, the average price target is $13.89. The highest price target for ABCL is $30.00, while the lowest price target for ABCL is $4.00. The average price target represents a forecasted upside of 17.45% from the current price of $11.83.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ABCL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbCellera Biologics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABCL Analyst Ratings Over Time

TypeCurrent Forecast
10/20/25 to 10/20/26
1 Month Ago
9/20/25 to 9/20/26
3 Months Ago
7/22/25 to 7/22/26
1 Year Ago
10/20/24 to 10/20/25
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$13.89$12.83$8.00$8.00
Forecasted Upside17.45% Upside1.61% Upside39.62% Upside36.52% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ABCL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABCL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbCellera Biologics Stock vs. The Competition

TypeAbCellera BiologicsHealthcare CompaniesBroader Market
Consensus Rating Score
2.80
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside18.81% Upside1,219.08% Upside17.47% Upside
News Sentiment Rating
Positive News

See Recent ABCL News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/15/2026
Weiss Ratings logo
Weiss Ratings
3 of 5 stars
 Reiterated RatingSell (D-)
10/12/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Initiated CoverageBuy$18.00+43.43%
9/29/2026
Brian Cheng
Brian Cheng
5 of 5 stars
Initiated CoverageOverweight$17.00+22.13%
9/24/2026Initiated CoverageNeutral$13.00+5.61%
8/11/2026Boost TargetBuy$12.00 ➝ $30.00+203.80%
8/6/2026Boost TargetBuy$8.00 ➝ $9.00+44.81%
8/6/2026Boost TargetOverweight$11.00 ➝ $12.00+102.70%
7/7/2026UpgradeHold ➝ Buy$11.00+39.77%
4/10/2026Initiated CoverageBuy$11.00+219.77%
11/7/2025 DowngradeStrong-Buy ➝ Hold
Why Some AI Stocks Already Surged Over 300 Percent (Ad)

Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel

See the light-speed AI technology and get Jason's number one pick free
7/14/2025Boost TargetOverweight$5.00 ➝ $10.00+149.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:01 PM ET.


ABCL Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for AbCellera Biologics is $13.89, with a high forecast of $30.00 and a low forecast of $4.00.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There is currently 1 sell rating, 2 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABCL shares.

According to analysts, AbCellera Biologics's stock has a predicted upside of 17.45% based on their 12-month stock forecasts.

Over the previous 90 days, AbCellera Biologics's stock had 1 upgrade by analysts.

AbCellera Biologics has been rated by research analysts at Cantor Fitzgerald, JPMorgan Chase & Co., Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like AbCellera Biologics more than other "healthcare" companies. The consensus rating for AbCellera Biologics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABCL compares to other companies.


MarketBeat monitors more than a dozen sources for AbCellera Biologics analyst ratings, with the most recent rating issued on 10/15/2026.
From Our Partners